Endeavor BioMedicines’ Post

🔔 Welcome you to read one of our papers published "Synthetic Vesicle-Based #Drug Delivery Systems for #Oral #Disease #Therapy: Current Applications and Future Directions" by Prof. Dr. Bo Yang et al. 🔗 𝐋𝐢𝐧𝐤 for 𝐭𝐡𝐞 𝐩𝐚𝐩𝐞𝐫: https://lnkd.in/dqH_M_Xi 🎓This review provides an in-depth examination of the characteristics, advantages, and limitations of #liposomes, #polymersomes, and #extracellular vesicles in the context of oral disease treatment. #MDPI #openaccess #openscience #learning #research #publishing #biomedicine

The aplastic anemia market is projected to grow from $6.26B in 2023 to $8.36B by 2028, with a CAGR of 6.0%. Growth drivers include rising blood disorders, demand for personalized medicine, and regulatory support. Key trends involve gene-editing technologies, telemedicine, biomarkers, and patient-specific therapies. Strategic partnerships, like Hemanext’s collaboration with AAMDS, aim to advance research and treatment. Major players include Pfizer, Novartis, and Roche. Read more https://lnkd.in/gTyfScgZ #AplasticAnemia #PersonalizedMedicine #GeneEditing #Biotech #HealthcareInnovation #BloodDisorders #Telemedicine #marketresearch #marketintelligence #marketreport #industryanalysis #TheBusinessResearchCompany #TBRC #GlobalMarketModel

Celebrate Excellence With Our Annual ServiceTrak Clinical Reports The time has come! Our annual ServiceTrak Clinical Reports are available now. These comprehensive reports highlight the top-performing clinical lab equipment manufacturers based on direct feedback from healthcare professionals. Discover which companies lead in service satisfaction, system performance, and overall customer performance. Reports offered across individual modalities. Learn More Here: https://hubs.la/Q02GBK3w0 #Healthcare #LabEquipment #ClinicalReport #CustomerSatisfaction #ServiceTrak #Immunology #Chemistry #Integrated #Coagulation #hematology #AST/ID #BloodCulture #MolecularDiagnostics #Urinalysis #BloodGas #Lab

In a laboratory machine, such as a hematology analyzer, a "flag" and an "alarm" serve as notifications to indicate potential issues or abnormal results. The main difference between them is: Flag: 🚩 - A flag is a warning or a notification that indicates a potential issue or an unusual result that requires attention. - It suggests that the result may be inaccurate or requires further verification. - Flags are often used to indicate abnormalities in results, such as unusual cell populations, inconsistent data, or potential instrument errors. - Flags typically require manual review and verification by a laboratory professional. Alarm: 📢 - An alarm is a critical notification that indicates a serious issue or a life-threatening result. - It signals that the result is significantly abnormal and requires immediate attention. - Alarms are often used to indicate critical results, such as extremely high or low values, that may require immediate medical intervention. - Alarms typically require immediate action and notification to a laboratory professional or a healthcare provider. Flags are warnings that require attention and verification, while alarms are critical notifications that require immediate action. In a 3-part differential Hematology analyzer, the following are some common pathological alarms or flags Part 1: White Blood Cell (WBC) Count - High WBC count (>20,000/μL): potential infection or inflammation - Low WBC count (<4,000/μL): potential immunodeficiency or bone marrow suppression Part 2: Red Blood Cell (RBC) Count - High RBC count (>6,000,000/μL): potential polycythemia or dehydration - Low RBC count (<4,000,000/μL): potential anemia or bleeding Part 3: Platelet Count - High platelet count (>500,000/μL): potential thrombocythemia or inflammation - Low platelet count (<100,000/μL): potential thrombocytopenia or bleeding disorder Other flags: - Anisocytosis (unequal RBC size) - Poikilocytosis (abnormal RBC shape) - Leukocytosis (increased WBC count) - Lymphocytosis (increased lymphocyte count) - Monocytosis (increased monocyte count) - Eosinophilia (increased eosinophil count) - Basophilia (increased basophil count) #pathologist #Hematologist #Hematology #laboratory #lab #mlt #ASCP #dha

🙈Do you worry about losing your sight with age? OphtiMed Rx is an innovative #biopharmaceutical company pioneering treatments for dry Age-Related Macular Degeneration (AMD), a top cause of vision loss worldwide. AMD affects over 60 million people in Europe and North America, with no approved treatments for early-to-intermediate stages, presenting a multibillion-dollar unmet need. 💡But do not worry!!! The company targets the aging process underlying AMD with OM-301, a first-in-class anti-senescence drug, that has shown robust preclinical results protecting retinal cells from senescence and degeneration, potentially halting disease progression. Backed by a world-class team of experts in ophthalmology, molecular biology, out-licensing, and M&A, OphtiMedRx aims to redefine the paradigm of AMD treatment. Let's help them solve this problem! To learn more about OphtiMed Rx visit their website: www.ophtimedrx.com 🤝 To meet with them at #jpmc25 sign up this sheet: https://lnkd.in/dp9fZ2XZ Contact info@ci-cc.org to get their 1-pager or deck Dana Rabinovich Ayala Pollack @Luis Iglesias Galil Ofek Innovation Eyal Aviram Sarah Amouyal #ophthalmology #investmentopportunity Sharon Vanek #drugdevelopment

Tissue Diagnostics Market Worth to reach $8.4 billion by 2028 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞 𝐚𝐭 https://lnkd.in/d_ebZbey The global tissue diagnostics market in terms of revenue was estimated to be worth $5.6 billion in 2023 and is poised to reach $8.4 billion by 2028, growing at a CAGR of 8.4% from 2023 to 2028. 𝐓𝐡𝐞 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐝 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐫𝐞𝐩𝐨𝐫𝐭 𝐢𝐧𝐜𝐥𝐮𝐝𝐞 Danaher PHC Holdings Corporation Thermo Fisher Scientific Abbott Agilent Technologies Merck Sakura Finetek Japan Co.,Ltd. abcam BD Bio SB, Inc. BioGenex Cell Signaling Technology (CST) Histo-Line Laboratories Srl SLEE medical GmbH CellPath, a StatLab Company Amos Scientific Pty. Ltd. Jinhua Yidi Medical Appliance CO.,LTD MEDITE Medical GmbH Diapath S.p.A KFBIO Konfoong Bioinformation Tech Diagnostic BioSystems 3DHISTECH - The Digital Pathology Company RWD Life Science Dakewe Medical Sysmex America, Inc. Enzo Life Sciences, Inc. BioCare Medical Company Milestone Medical BIO-OPTICA MILANO S.P.A. 𝐎𝐭𝐡𝐞𝐫 𝐜𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐭𝐡𝐚𝐭 𝐚𝐫𝐞 𝐨𝐩𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐢𝐧 𝐭𝐡𝐢𝐬 𝐦𝐚𝐫𝐤𝐞𝐭 𝐠𝐥𝐨𝐛𝐚𝐥𝐥𝐲 Sakura Finetek USA MedConsult Clinic Pathology Diagnostics Ltd. Genomic Health OMNI International NanoString Technologies, Inc. PathAI Diagnostics Tissue Solutions Limited PHENOPATH PHYSICIANS, PLLC Horizon Discovery GENOPTIX INC., DBA GENOPTIX MEDICAL LABORATORY NantHealth

We’re thrilled to share that Juventix Regenerative Medical has been featured in a clinical research study from 𝘍𝘭𝘰𝘳𝘪𝘥𝘢 𝘐𝘯𝘵𝘦𝘳𝘯𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘜𝘯𝘪𝘷𝘦𝘳𝘴𝘪𝘵𝘺 (FIU)! This peer-reviewed study, published in the journal 𝘊𝘶𝘳𝘦𝘶𝘴, highlights the transformative potential of Juventix PRP (Platelet-Rich Plasma) technology in managing rheumatoid arthritis (RA). By reducing joint pain, supporting tissue repair, and offering a promising non-surgical alternative, Juventix PRP continues to showcase real-world value in patient care. This research builds on earlier lab validations, confirming significant platelet recovery, elevated growth factor levels, minimal contamination, and optimal conditions for advanced PRP preparation. To celebrate this milestone and introduce more medical professionals to the benefits of Juventix PRP, we’re offering a 𝒍𝒊𝒎𝒊𝒕𝒆𝒅-𝒕𝒊𝒎𝒆 𝒔𝒂𝒎𝒑𝒍𝒆 𝑷𝑹𝑷 𝒌𝒊𝒕 𝒇𝒐𝒓 𝒋𝒖𝒔𝒕 $20. Take advantage of this opportunity to experience next-generation, science-backed regenerative solutions firsthand! 📰 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐩𝐫𝐞𝐬𝐬 𝐫𝐞𝐥𝐞𝐚𝐬𝐞 𝐡𝐞𝐫𝐞: https://lnkd.in/gWdyE7WR 📧𝐅𝐨𝐫 𝐦𝐨𝐫𝐞 𝐢𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 𝐨𝐧 𝐬𝐚𝐦𝐩𝐥𝐞 𝐤𝐢𝐭𝐬 𝐩𝐥𝐞𝐚𝐬𝐞 𝐞𝐦𝐚𝐢𝐥: hello@juventix.com (Subject Line: “SAMPLE”) 🌐𝐎𝐫 𝐯𝐢𝐬𝐢𝐭: https://lnkd.in/gAWQkXnN 𝐑𝐞𝐬𝐭𝐨𝐫𝐞, 𝐑𝐞𝐯𝐢𝐯𝐞, 𝐑𝐞𝐠𝐞𝐧𝐞𝐫𝐚𝐭𝐞. #RegenerativeMedicine #PRP #RheumatoidArthritis #ClinicalResearch #HealthcareInnovation #PatientCare #NonSurgicalSolutions #Biotech #MedicalResearch #Juventix

Histology and Cytology IVD Market Update 2024 with Profiles of the Top 5 Players - Agilent, Danaher, Hologic, Illumina, & Roche Diagnostics - ResearchAndMarkets.com DUBLIN--(BUSINESS WIRE)--The "Histology and Cytology IVD Market Update, 2024" report has been added to ResearchAndMarkets.com's offering. This report provides a competitive analysis of the histology/cytology market from 2023 to 2028. Histology/cytology has been a mainstay of the pathological lab, providing information about cells, tissues and organs. Competitive analysis is provided for the top five participants in the market. The forecasted market analysis for 2023-2028 was largely based on de via Business Wire Health: Medical Devices News

Organoids on a Chip: Development and Applications The integration of organoid technology with microfluidic chips, organoids on a chip, has revolutionized biomedical research by combining the physiological relevance of organoids with the dynamic, precisely controlled environment of organ-on-a-chip systems. This innovation provides a powerful platform for studying complex biological processes and disease mechanisms in a highly controllable and scalable manner. 1. Development of Organoids on a Chip Organoids on a chip are developed by embedding organoids (3D structures that mimic the specific structure and function of an organ) into microfluidic devices. These chips are designed to replicate physiological conditions such as nutrient supply, oxygen gradients, and mechanical forces using a perfusion system. Advanced fabrication techniques and biomaterials ensure compatibility with a variety of organoid types, including intestinal, brain, lung, and liver organoids. The inclusion of sensors enables real-time monitoring of cellular responses, thereby increasing the precision and utility of the system. 2. Applications in Research and Medicine (1) Disease Modeling: Organoids on a chip enable researchers to replicate complex disease environments such as cancer progression, neurodegenerative diseases, and viral infections. These models provide insights into disease mechanisms that are difficult to achieve using traditional 2D cultures or animal models. (2) Drug Discovery and Toxicology: The system facilitates high-throughput screening and toxicity testing of drug candidates, providing predictive models for human responses. Organoids on a chip bridge the gap between in vitro and in vivo studies, improving the efficiency of the drug development process. (3) Precision Medicine: By using patient-derived organoids, organoids on a chip can enable personalized testing of therapeutic interventions, thereby optimizing treatment strategies for individual patients. (4) Systems Biology Research: The dynamic environment of the chip supports the study of multi-organ interactions and complex signaling, thereby deepening our understanding of systems biology. Organoids on a chip represent a transformative advance in biomedical research, providing unprecedented opportunities to study human physiology and disease with precision, scalability, and relevance. The technology is expected to accelerate innovation in diagnostics, therapeutics, and personalized medicine. If you are interested in our Organoids on a Chip, please contact us at csteam-biomed@hotmail.com #OrganoidsOnChips #BiomedicalResearch #DiseaseModeling #DrugDiscovery #PrecisionMedicine #Microfluidics #OrganoidTechnology #ToxicologyTesting #PersonalizedMedicine #InnovationInScience #Newsletter